




Searching News Database: fibrosis
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 4 Apr 2025
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
HSMN NewsFeed - 23 Oct 2024
Alphina Therapeutics Appoints Veteran Biotech Executive, Nick Galli, as Chief Executive Officer
Alphina Therapeutics Appoints Veteran Biotech Executive, Nick Galli, as Chief Executive Officer
HSMN NewsFeed - 8 Jul 2024
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
HSMN NewsFeed - 23 Apr 2024
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
HSMN NewsFeed - 15 Dec 2023
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
HSMN NewsFeed - 6 Nov 2023
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
HSMN NewsFeed - 12 Aug 2022
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities
HSMN NewsFeed - 1 Aug 2022
Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections
Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections
HSMN NewsFeed - 20 Jul 2022
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug
HSMN NewsFeed - 20 Jul 2022
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
HSMN NewsFeed - 21 Jun 2022
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
HSMN NewsFeed - 19 May 2022
Odyssey Therapeutics Appoints Industry Leader Jeffrey M. Leiden, M.D., Ph.D., as Board Chair
Odyssey Therapeutics Appoints Industry Leader Jeffrey M. Leiden, M.D., Ph.D., as Board Chair
HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
HSMN NewsFeed - 3 Feb 2022
Third Pole Therapeutics Closes $25M Financing - eNOfit(TM) Wearable Device Now Ready for Clinical Trials
Third Pole Therapeutics Closes $25M Financing - eNOfit(TM) Wearable Device Now Ready for Clinical Trials
HSMN NewsFeed - 7 Dec 2021
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 3 Dec 2021
Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer
Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer
HSMN NewsFeed - 2 Sep 2021
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
HSMN NewsFeed - 15 Jul 2021
iSTAR Medical receives U.S. FDA approval to start pivotal trial for MINIject in glaucoma patients
iSTAR Medical receives U.S. FDA approval to start pivotal trial for MINIject in glaucoma patients
HSMN NewsFeed - 15 Apr 2021
Third Pole Therapeutics Secures $15 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.
Third Pole Therapeutics Secures $15 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.
HSMN NewsFeed - 16 Nov 2020
iSTAR Medical's glaucoma device MINIject shows positive one-year results in European trial
iSTAR Medical's glaucoma device MINIject shows positive one-year results in European trial
HSMN NewsFeed - 26 Oct 2020
Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development
Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development
HSMN NewsFeed - 24 Aug 2020
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
HSMN NewsFeed - 26 May 2020
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
HSMN NewsFeed - 13 May 2020
Spirovant Sciences Appoints Roland Kolbeck, PhD, as Chief Scientific Officer
Spirovant Sciences Appoints Roland Kolbeck, PhD, as Chief Scientific Officer
HSMN NewsFeed - 3 Mar 2020
Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases
Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases
HSMN NewsFeed - 14 Feb 2020
Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board
Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board
HSMN NewsFeed - 23 Jan 2020
iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Development
iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Development
HSMN NewsFeed - 2 Jan 2020
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
HSMN NewsFeed - 19 Dec 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
HSMN NewsFeed - 6 Dec 2019
Apexigen Expands Leadership Team with Two Key Appointments in CMC and Clinical Development
Apexigen Expands Leadership Team with Two Key Appointments in CMC and Clinical Development
HSMN NewsFeed - 18 Oct 2019
Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
HSMN NewsFeed - 10 Oct 2019
FDA Grants Ofev(R) Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
FDA Grants Ofev(R) Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
HSMN NewsFeed - 19 Jul 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
HSMN NewsFeed - 10 Jun 2019
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
HSMN NewsFeed - 23 Apr 2019
Akero Therapeutics Appoints Industry Veteran Jane Pritchett Henderson to Board of Directors
Akero Therapeutics Appoints Industry Veteran Jane Pritchett Henderson to Board of Directors
HSMN NewsFeed - 3 Apr 2019
Varian Discloses First Preclinical Results of Potential Major Breakthrough in Cancer Treatment
Varian Discloses First Preclinical Results of Potential Major Breakthrough in Cancer Treatment
HSMN NewsFeed - 27 Mar 2019
Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer
Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer
HSMN NewsFeed - 6 Feb 2019
Proteostasis Therapeutics Appoints Emmanuel Dulac and Kim Drapkin to Board of Directors
Proteostasis Therapeutics Appoints Emmanuel Dulac and Kim Drapkin to Board of Directors
HSMN NewsFeed - 30 Jan 2019
ArcherDX Acquires Baby Genes, a Genetics-Based Personalized Medicine Company
ArcherDX Acquires Baby Genes, a Genetics-Based Personalized Medicine Company
HSMN NewsFeed - 28 Jan 2019
Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO
Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO
HSMN NewsFeed - 17 Dec 2018
Proteostasis Therapeutics Announces Global License Agreement with Genentech
Proteostasis Therapeutics Announces Global License Agreement with Genentech
HSMN NewsFeed - 25 Oct 2018
89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
HSMN NewsFeed - 25 Sep 2018
Dr. Dmitry Samarsky Joins Sirnaomics Senior Management Team as Chief Technology Officer
Dr. Dmitry Samarsky Joins Sirnaomics Senior Management Team as Chief Technology Officer
HSMN NewsFeed - 17 Sep 2018
Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate
Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate
HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
HSMN NewsFeed - 16 Jul 2018
Pliant Therapeutics Raises $62 Million in Series B Financing to Advance Therapies for Fibrotic Diseases
Pliant Therapeutics Raises $62 Million in Series B Financing to Advance Therapies for Fibrotic Diseases
HSMN NewsFeed - 11 Jun 2018
Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update
Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update
HSMN NewsFeed - 8 May 2018
Pliant Therapeutics Appoints Hoyoung Huh as Chairman and Éric Lefebvre as Chief Medical Officer
Pliant Therapeutics Appoints Hoyoung Huh as Chairman and Éric Lefebvre as Chief Medical Officer
HSMN NewsFeed - 9 Mar 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
HSMN NewsFeed - 5 Feb 2018
FDA Clears Oricula Therapeutics Investigational New Drug Application for Clinical Trials
FDA Clears Oricula Therapeutics Investigational New Drug Application for Clinical Trials
HSMN NewsFeed - 22 Jan 2018
Symic Bio Appoints Hicham Alaoui, Ph.D., as Senior Vice President of Discovery Biology
Symic Bio Appoints Hicham Alaoui, Ph.D., as Senior Vice President of Discovery Biology
HSMN NewsFeed - 27 Dec 2017
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
HSMN NewsFeed - 7 Dec 2017
Metacrine Completes Series B Financing to Advance Best-in-Class FXR Program into Clinical Development
Metacrine Completes Series B Financing to Advance Best-in-Class FXR Program into Clinical Development
HSMN NewsFeed - 4 Dec 2017
Led by OrbiMed Israel and Peter Thiel, ChemomAb Raises $10 Million in Series B Funding
Led by OrbiMed Israel and Peter Thiel, ChemomAb Raises $10 Million in Series B Funding
HSMN NewsFeed - 30 Nov 2017
Fractyl Completes $44 Million Series D Financing to Advance New Treatment for Type 2 Diabetes
Fractyl Completes $44 Million Series D Financing to Advance New Treatment for Type 2 Diabetes
HSMN NewsFeed - 3 Nov 2017
Symic Bio Appoints Wayne Froland, Ph.D., as Executive Vice President of Technical Operations
Symic Bio Appoints Wayne Froland, Ph.D., as Executive Vice President of Technical Operations
HSMN NewsFeed - 24 Oct 2017
KNOW Bio Strengthens Leadership with the Addition of Four New Board Members
KNOW Bio Strengthens Leadership with the Addition of Four New Board Members
HSMN NewsFeed - 26 Sep 2017
CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions
CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions
HSMN NewsFeed - 20 Sep 2017
Arvinas Appoints Dr. John Houston as President and Chief Executive Officer
Arvinas Appoints Dr. John Houston as President and Chief Executive Officer
HSMN NewsFeed - 24 Jul 2017
CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors
CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors
HSMN NewsFeed - 9 Jun 2017
Kleo Pharmaceuticals Inc. Appoints Douglas J. Manion M.D. as Chief Executive Officer
Kleo Pharmaceuticals Inc. Appoints Douglas J. Manion M.D. as Chief Executive Officer
HSMN NewsFeed - 23 May 2017
IFM Therapeutics Appoints H. Martin Seidel as Executive Vice President of Research and Development
IFM Therapeutics Appoints H. Martin Seidel as Executive Vice President of Research and Development
HSMN NewsFeed - 8 May 2017
Lamellar Biomedical Raises ÂŁ5.75 Million in Series C Fund Raising led by Invesco
Lamellar Biomedical Raises ÂŁ5.75 Million in Series C Fund Raising led by Invesco
HSMN NewsFeed - 26 Apr 2017
FDA Approves XATMEP(TM), the First and Only Ready-To-Use Methotrexate Oral Solution
FDA Approves XATMEP(TM), the First and Only Ready-To-Use Methotrexate Oral Solution
HSMN NewsFeed - 18 Apr 2017
Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration
Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration
HSMN NewsFeed - 11 Apr 2017
Valeo Pharma and Zambon form partnership for Parkinson's Disease Treatment Xadago(R) (safinamide) in Canada
Valeo Pharma and Zambon form partnership for Parkinson's Disease Treatment Xadago(R) (safinamide) in Canada
HSMN NewsFeed - 14 Feb 2017
miRagen Therapeutics Completes Merger with Signal Genetics and Concurrent $40.7 Million Equity Financing
miRagen Therapeutics Completes Merger with Signal Genetics and Concurrent $40.7 Million Equity Financing
HSMN NewsFeed - 24 Oct 2016
Efficacy of Ofev(R) (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST
Efficacy of Ofev(R) (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST
HSMN NewsFeed - 12 Oct 2016
Global Blood Therapeutics Announces Appointment of Tricia Suvari as Chief Legal Officer
Global Blood Therapeutics Announces Appointment of Tricia Suvari as Chief Legal Officer
HSMN NewsFeed - 5 Oct 2016
Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor
Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor
HSMN NewsFeed - 24 Aug 2016
Telesta Therapeutics Announces Execution of a Binding Purchase Agreement from ProMetic Life Sciences Inc.
Telesta Therapeutics Announces Execution of a Binding Purchase Agreement from ProMetic Life Sciences Inc.
HSMN NewsFeed - 3 May 2016
Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors
Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors
HSMN NewsFeed - 7 Apr 2016
VolitionRx Announces CE Marks for Two NuQ(R) Blood Assays for Detection of Colorectal Cancer
VolitionRx Announces CE Marks for Two NuQ(R) Blood Assays for Detection of Colorectal Cancer
HSMN NewsFeed - 7 Mar 2016
Anthera Pharmaceuticals Announces Appointment of Dr. James Pennington as Interim Chief Medical Officer
Anthera Pharmaceuticals Announces Appointment of Dr. James Pennington as Interim Chief Medical Officer
HSMN NewsFeed - 29 Feb 2016
Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma
Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma
HSMN NewsFeed - 23 Feb 2016
PTC Receives Refuse to File Letter from FDA for Translarna(TM) (ataluren)
PTC Receives Refuse to File Letter from FDA for Translarna(TM) (ataluren)
HSMN NewsFeed - 20 Jan 2016
Monaghan Medical Introduces Manometer Adapter to Measure Treatment With Aerobika(R) OPEP Device
Monaghan Medical Introduces Manometer Adapter to Measure Treatment With Aerobika(R) OPEP Device
HSMN NewsFeed - 13 Jan 2016
Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib
Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib
HSMN NewsFeed - 23 Nov 2015
Vertex Appoints Michael J. Parini as Executive Vice President and Chief Legal Officer
Vertex Appoints Michael J. Parini as Executive Vice President and Chief Legal Officer
HSMN NewsFeed - 9 Nov 2015
Spring Bank Pharmaceuticals Names Nezam Afdhal, MD as Chief Medical Officer
Spring Bank Pharmaceuticals Names Nezam Afdhal, MD as Chief Medical Officer
HSMN NewsFeed - 27 Oct 2015
Allergan Acquires Rights To Ironwood's CONSTELLA(R) (Linaclotide) From Almirall In More Than 40 Countries
Allergan Acquires Rights To Ironwood's CONSTELLA(R) (Linaclotide) From Almirall In More Than 40 Countries
HSMN NewsFeed - 31 Aug 2015
FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
HSMN NewsFeed - 25 Aug 2015
Regulus Appoints Michael Huang, M.D. as Vice President, Clinical Development
Regulus Appoints Michael Huang, M.D. as Vice President, Clinical Development
HSMN NewsFeed - 27 May 2015
Zafgen Appoints Global Head of Medical Affairs and Global Head of Regulatory
Zafgen Appoints Global Head of Medical Affairs and Global Head of Regulatory
HSMN NewsFeed - 14 Apr 2015
Eiger BioPharmaceuticals Announces Senior Staff Appointments in Clinical Development and Regulatory Affairs
Eiger BioPharmaceuticals Announces Senior Staff Appointments in Clinical Development and Regulatory Affairs
HSMN NewsFeed - 12 Jan 2015
CTI BioPharma Appoints Alan K. Burnett, M.D. As Therapeutic Area Lead, Myeloid Diseases
CTI BioPharma Appoints Alan K. Burnett, M.D. As Therapeutic Area Lead, Myeloid Diseases
HSMN NewsFeed - 3 Jul 2014
Akashi Therapeutics Receives Collective Funding of $1.5 Million to Support HT-100 Clinical Development
Akashi Therapeutics Receives Collective Funding of $1.5 Million to Support HT-100 Clinical Development
HSMN NewsFeed - 30 Jun 2014
Proteostasis Therapeutics Appoints Meenu Chhabra as Chief Executive Officer
Proteostasis Therapeutics Appoints Meenu Chhabra as Chief Executive Officer
HSMN NewsFeed - 19 Jun 2014
Tyrogenex Raises $15M in Series D Financing from Brace Pharma, US Investment Arm of EMS S/A
Tyrogenex Raises $15M in Series D Financing from Brace Pharma, US Investment Arm of EMS S/A
HSMN NewsFeed - 15 Apr 2014
AAVLife Raises $12 Million in Series A Financing to Advance Gene Therapy for Friedreich’s Ataxia
AAVLife Raises $12 Million in Series A Financing to Advance Gene Therapy for Friedreich’s Ataxia
HSMN NewsFeed - 13 Mar 2014
Synergy Pharmaceuticals Appoints Marino Garcia as Senior Vice President, Corporate Development
Synergy Pharmaceuticals Appoints Marino Garcia as Senior Vice President, Corporate Development
HSMN NewsFeed - 25 Feb 2014
InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)
InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)
HSMN NewsFeed - 18 Feb 2014
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction
HSMN NewsFeed - 14 Jan 2014
Actavis Appoints Industry Veterans to Lead U.S. Specialty Brands Business Units
Actavis Appoints Industry Veterans to Lead U.S. Specialty Brands Business Units
HSMN NewsFeed - 30 Dec 2013
Electromed, Inc. Receives FDA Market Clearance for the SmartVest(R) SQL(TM)
Electromed, Inc. Receives FDA Market Clearance for the SmartVest(R) SQL(TM)
HSMN NewsFeed - 12 Dec 2013
Momenta Pharmaceuticals Appoints Michael Franken, M.D. as President, Biosimilars Business
Momenta Pharmaceuticals Appoints Michael Franken, M.D. as President, Biosimilars Business
HSMN NewsFeed - 21 Nov 2013
Eloxx Pharmaceuticals, Ltd. Announced the Initial Closing of its First Round of Financing
Eloxx Pharmaceuticals, Ltd. Announced the Initial Closing of its First Round of Financing
HSMN NewsFeed - 15 Nov 2013
Germ-Zapping Robots Use Xenex’s Powerful, Pulsed UV Light to Improve Patient Safety at University Hospital
Germ-Zapping Robots Use Xenex’s Powerful, Pulsed UV Light to Improve Patient Safety at University Hospital
HSMN NewsFeed - 28 Oct 2013
Arcturus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., as Chief Business Officer
Arcturus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., as Chief Business Officer
HSMN NewsFeed - 24 Oct 2013
Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
HSMN NewsFeed - 16 Oct 2013
Newly Established Medac Pharma, Inc. Appoints Industry Veteran Terri Shoemaker as President and CEO
Newly Established Medac Pharma, Inc. Appoints Industry Veteran Terri Shoemaker as President and CEO
HSMN NewsFeed - 23 Sep 2013
Bayer receives approval for Adempas(R) as first drug to treat rare heart and lung disease
Bayer receives approval for Adempas(R) as first drug to treat rare heart and lung disease
HSMN NewsFeed - 3 Sep 2013
Aptalis Pharma(TM) Launches PYLERA(R) 10 Day Therapy PAK in the United States
Aptalis Pharma(TM) Launches PYLERA(R) 10 Day Therapy PAK in the United States
HSMN NewsFeed - 13 Jun 2013
PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
HSMN NewsFeed - 22 May 2013
Syros Pharmaceuticals Appoints Eric R. Olson, Ph.D. as Chief Scientific Officer
Syros Pharmaceuticals Appoints Eric R. Olson, Ph.D. as Chief Scientific Officer
HSMN NewsFeed - 28 Feb 2013
InVivo Therapeutics Submits Updated IDE to FDA to Begin Spinal Cord Injury Human Study
InVivo Therapeutics Submits Updated IDE to FDA to Begin Spinal Cord Injury Human Study
HSMN NewsFeed - 25 Feb 2013
First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
HSMN NewsFeed - 18 Dec 2012
Biogen Executive Kenneth DiPietro Joins InVivo Therapeutics Board of Directors
Biogen Executive Kenneth DiPietro Joins InVivo Therapeutics Board of Directors
HSMN NewsFeed - 27 Nov 2012
Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development
Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development
HSMN NewsFeed - 7 Nov 2012
Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
HSMN NewsFeed - 26 Oct 2012
NICE Approves Pharmaxis' Bronchitol(R) As An Important New Treatment Option For Cystic Fibrosis Patients
NICE Approves Pharmaxis' Bronchitol(R) As An Important New Treatment Option For Cystic Fibrosis Patients
HSMN NewsFeed - 22 Oct 2012
Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer
Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer
HSMN NewsFeed - 28 Sep 2012
PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors
PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors
HSMN NewsFeed - 20 Sep 2012
Third Rock Ventures Launches MyoKardia with $38 Million to Address Genetic Heart Disease
Third Rock Ventures Launches MyoKardia with $38 Million to Address Genetic Heart Disease
HSMN NewsFeed - 5 Sep 2012
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
HSMN NewsFeed - 4 Sep 2012
Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer
Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer
HSMN NewsFeed - 2 Aug 2012
Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
HSMN NewsFeed - 14 Jun 2012
GenMark Diagnostics Appoints Stephen T. Worland, Ph.D. to Board of Directors
GenMark Diagnostics Appoints Stephen T. Worland, Ph.D. to Board of Directors
HSMN NewsFeed - 15 May 2012
Promedior Appoints Suzanne L. Bruhn, Ph.D., as President and Chief Executive Officer
Promedior Appoints Suzanne L. Bruhn, Ph.D., as President and Chief Executive Officer
HSMN NewsFeed - 10 May 2012
RXi Pharmaceuticals Appoints Industry Veteran Dr. Geert Cauwenbergh as President and Chief Executive Officer
RXi Pharmaceuticals Appoints Industry Veteran Dr. Geert Cauwenbergh as President and Chief Executive Officer
HSMN NewsFeed - 27 Mar 2012
InterMune Appoints Mr. Jean-Jacques Bienaime and Dr. Frank Verwiel to Board of Directors
InterMune Appoints Mr. Jean-Jacques Bienaime and Dr. Frank Verwiel to Board of Directors
HSMN NewsFeed - 6 Mar 2012
Islet Sciences Names Dr. George J. Todaro and Dr. Jerry L. Nader to Board of Directors
Islet Sciences Names Dr. George J. Todaro and Dr. Jerry L. Nader to Board of Directors
HSMN NewsFeed - 24 Feb 2012
Forest Laboratories Receives European Marketing Approval for Colobreathe(R) Dry Powder Inhaler
Forest Laboratories Receives European Marketing Approval for Colobreathe(R) Dry Powder Inhaler
HSMN NewsFeed - 16 Feb 2012
GenMark Diagnostics Appoints Dr. Jorge Garces Senior Vice President, Research and Development
GenMark Diagnostics Appoints Dr. Jorge Garces Senior Vice President, Research and Development
HSMN NewsFeed - 20 Jan 2012
La Jolla Pharmaceutical Company Acquires GCS-100, a First-in-Class Galectin-3 Antagonist
La Jolla Pharmaceutical Company Acquires GCS-100, a First-in-Class Galectin-3 Antagonist
HSMN NewsFeed - 6 Dec 2011
Amgen and FDA Agree to Modify Nplate(R) (Romiplostim) Risk Evaluation and Mitigation Strategy
Amgen and FDA Agree to Modify Nplate(R) (Romiplostim) Risk Evaluation and Mitigation Strategy
HSMN NewsFeed - 1 Nov 2011
Conatus Pharmaceuticals Appoints Dr. Gary Burgess as Senior Vice President and Chief Medical Officer
Conatus Pharmaceuticals Appoints Dr. Gary Burgess as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 12 Sep 2011
FibroGen Appoints Michael Martinelli, Ph.D., Vice President of Technical Development
FibroGen Appoints Michael Martinelli, Ph.D., Vice President of Technical Development
HSMN NewsFeed - 15 Aug 2011
Pulmatrix Secures a $14 million Financing to Advance Clinical Programs in COPD and Cystic Fibrosis
Pulmatrix Secures a $14 million Financing to Advance Clinical Programs in COPD and Cystic Fibrosis
HSMN NewsFeed - 20 Jun 2011
Pulmatrix Launches iSPERSE(TM), A Novel Inhaled Dry Powder Drug Delivery Platform
Pulmatrix Launches iSPERSE(TM), A Novel Inhaled Dry Powder Drug Delivery Platform
HSMN NewsFeed - 12 Apr 2011
DARA BioSciences Reports That SurgiVision Has Completed a Commercial Alliance With Brainlab AG
DARA BioSciences Reports That SurgiVision Has Completed a Commercial Alliance With Brainlab AG
HSMN NewsFeed - 6 Apr 2011
GenMark Diagnostics Appoints Hany Massarany President and Chief Executive Officer
GenMark Diagnostics Appoints Hany Massarany President and Chief Executive Officer
HSMN NewsFeed - 22 Mar 2011
Synergy Pharmaceuticals Appoints Dr. Laura Barrow as Vice President of Clinical Operations
Synergy Pharmaceuticals Appoints Dr. Laura Barrow as Vice President of Clinical Operations
HSMN NewsFeed - 21 Mar 2011
Regulus Therapeutics Appoints Lars Karlsson, M.D., Ph.D., VP of Immunology and Fibrosis
Regulus Therapeutics Appoints Lars Karlsson, M.D., Ph.D., VP of Immunology and Fibrosis
HSMN NewsFeed - 15 Mar 2011
U.S. FDA Approves Bayer's Gadavist (Gadobutrol) Injection for MRI of the Central Nervous System
U.S. FDA Approves Bayer's Gadavist (Gadobutrol) Injection for MRI of the Central Nervous System
HSMN NewsFeed - 15 Mar 2011
Incyte’s Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study
Incyte’s Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study
HSMN NewsFeed - 25 Feb 2011
FDA Grants Full Approval for PROMACTA(R) (eltrombopag) for Treatment of Rare Blood Disorder
FDA Grants Full Approval for PROMACTA(R) (eltrombopag) for Treatment of Rare Blood Disorder
HSMN NewsFeed - 17 Feb 2011
Inspire Announces Corporate Restructuring and Strategic Focus on Eye Care Business
Inspire Announces Corporate Restructuring and Strategic Focus on Eye Care Business
HSMN NewsFeed - 21 Jan 2011
Lantheus Medical Imaging Announces New National Contract with Novation for ABLAVAR(R) and DEFINITY(R)
Lantheus Medical Imaging Announces New National Contract with Novation for ABLAVAR(R) and DEFINITY(R)
HSMN NewsFeed - 11 Jan 2011
SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom
SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom
HSMN NewsFeed - 3 Jan 2011
Inspire Announces Results of Second Phase 3 Trial with Denufosol for Cystic Fibrosis
Inspire Announces Results of Second Phase 3 Trial with Denufosol for Cystic Fibrosis
HSMN NewsFeed - 17 Dec 2010
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet (Pirfenidone) in Europe
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet (Pirfenidone) in Europe
HSMN NewsFeed - 17 Dec 2010
InterMune Announces Positive Opinion for Approval of Esbriet (Pirfenidone) in European Union
InterMune Announces Positive Opinion for Approval of Esbriet (Pirfenidone) in European Union
HSMN NewsFeed - 2 Dec 2010
Regulus Therapeutics Strengthens Immunology Leadership Team with New Key Appointment
Regulus Therapeutics Strengthens Immunology Leadership Team with New Key Appointment
HSMN NewsFeed - 2 Dec 2010
New Toshiba Vantage Titan HSR 1.5T Produces Outstanding Image Quality for Advanced MR Applications
New Toshiba Vantage Titan HSR 1.5T Produces Outstanding Image Quality for Advanced MR Applications
HSMN NewsFeed - 28 Oct 2010
Sanofi-Aventis Completes $10 Million Equity Investment in Regulus Therapeutics
Sanofi-Aventis Completes $10 Million Equity Investment in Regulus Therapeutics
HSMN NewsFeed - 14 Oct 2010
YM Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announces Annual Meeting
YM Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announces Annual Meeting
HSMN NewsFeed - 1 Sep 2010
Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer
Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer
HSMN NewsFeed - 6 Jul 2010
Three Rivers Pharmaceuticals Announces FDA Approval Of Expanded Labeling of INFERGEN
Three Rivers Pharmaceuticals Announces FDA Approval Of Expanded Labeling of INFERGEN
HSMN NewsFeed - 16 Jun 2010
Eurand Names Former Solvay Executive Jean-Louis Anspach President of U.S. Pharmaceuticals Business
Eurand Names Former Solvay Executive Jean-Louis Anspach President of U.S. Pharmaceuticals Business
HSMN NewsFeed - 1 Jun 2010
Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus
Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus
HSMN NewsFeed - 26 Apr 2010
Osmetech plc Receives 510(k) Clearance for the eSensor(R) Thrombophilia Risk Test
Osmetech plc Receives 510(k) Clearance for the eSensor(R) Thrombophilia Risk Test
HSMN NewsFeed - 13 Apr 2010
Inspire Appoints Andrew Koven as Executive Vice President and Chief Administrative and Legal Officer
Inspire Appoints Andrew Koven as Executive Vice President and Chief Administrative and Legal Officer
HSMN NewsFeed - 2 Mar 2010
InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
HSMN NewsFeed - 11 Jan 2010
Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
HSMN NewsFeed - 16 Dec 2009
GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment
GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment
HSMN NewsFeed - 10 Dec 2009
Vertex Pharmaceuticals Announces Appointment of Nancy J. Wysenski as Chief Commercial Officer
Vertex Pharmaceuticals Announces Appointment of Nancy J. Wysenski as Chief Commercial Officer
HSMN NewsFeed - 17 Nov 2009
Abbott to Develop New Heart Failure Test on ARCHITECT(R) Immunochemistry Diagnostics Platform
Abbott to Develop New Heart Failure Test on ARCHITECT(R) Immunochemistry Diagnostics Platform
HSMN NewsFeed - 5 Nov 2009
InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
HSMN NewsFeed - 3 Nov 2009
Alnara Pharmaceuticals Announces Appointment of Lee R. Brettman, M.D., FACP, to Chief Medical Officer
Alnara Pharmaceuticals Announces Appointment of Lee R. Brettman, M.D., FACP, to Chief Medical Officer
HSMN NewsFeed - 10 Sep 2009
PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
HSMN NewsFeed - 22 Jun 2009
FDA Extends Review Period for Eurand's ZENPEP(TM) Pancreatic Enzyme Replacement Therapy
FDA Extends Review Period for Eurand's ZENPEP(TM) Pancreatic Enzyme Replacement Therapy
HSMN NewsFeed - 29 May 2009
UCB receives CHMP positive opinion on bringing Neupro(R) back to all patients in Europe
UCB receives CHMP positive opinion on bringing Neupro(R) back to all patients in Europe
HSMN NewsFeed - 29 Jan 2009
FDA Accepts Eurand's Response to Approvable Letter for EUR-1008 as Complete
FDA Accepts Eurand's Response to Approvable Letter for EUR-1008 as Complete
HSMN NewsFeed - 29 Jan 2009
FDA Provides Clear Path to NDA Submission for Pro-Pharmaceuticals’ DAVANAT(R)
FDA Provides Clear Path to NDA Submission for Pro-Pharmaceuticals’ DAVANAT(R)
HSMN NewsFeed - 22 Dec 2008
EPIX Pharmaceuticals Announces FDA Approval of Vasovist(R) (gadofosveset trisodium)
EPIX Pharmaceuticals Announces FDA Approval of Vasovist(R) (gadofosveset trisodium)
HSMN NewsFeed - 22 Dec 2008
KaloBios Raises Additional $12 Million in Series D Venture Financing for a New Total of $32 Million
KaloBios Raises Additional $12 Million in Series D Venture Financing for a New Total of $32 Million
HSMN NewsFeed - 6 Oct 2008
Study Shows PillCam(R) ESO Reduces Prison Health Care Costs by 90% for Cirrhotic Patients
Study Shows PillCam(R) ESO Reduces Prison Health Care Costs by 90% for Cirrhotic Patients
HSMN NewsFeed - 4 Sep 2008
EPIX Pharmaceuticals To Regain Full Worldwide Commercial Rights For Vasovist(R)
EPIX Pharmaceuticals To Regain Full Worldwide Commercial Rights For Vasovist(R)
HSMN NewsFeed - 12 Aug 2008
Stromedix Receives Orphan Drug Designation for STX-100 in Chronic Allograft Nephropathy
Stromedix Receives Orphan Drug Designation for STX-100 in Chronic Allograft Nephropathy
HSMN NewsFeed - 11 Aug 2008
U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults
U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults
HSMN NewsFeed - 28 Jul 2008
EPIX Pharmaceuticals Announces Resignation of CEO; Names Elkan Gamzu Interim CEO
EPIX Pharmaceuticals Announces Resignation of CEO; Names Elkan Gamzu Interim CEO
HSMN NewsFeed - 21 Jul 2008
FDA Clears Osmetech's Warfarin Sensitivity Test and New eSensor(R) XT-8 Platform
FDA Clears Osmetech's Warfarin Sensitivity Test and New eSensor(R) XT-8 Platform
HSMN NewsFeed - 1 Jul 2008
EPIX Pharmaceuticals Announces Resubmission of New Drug Application for Vasovist(R)
EPIX Pharmaceuticals Announces Resubmission of New Drug Application for Vasovist(R)
HSMN NewsFeed - 6 Jun 2008
Inspire Announces Achievement of Primary Endpoint in Phase 3 Trial with Denufosol for Cystic Fibrosis
Inspire Announces Achievement of Primary Endpoint in Phase 3 Trial with Denufosol for Cystic Fibrosis
HSMN NewsFeed - 3 Jun 2008
Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics
Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics
HSMN NewsFeed - 19 May 2008
InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
Additional items found! 276

Members Archive contains
276 additional stories matching:
fibrosis
(Password required)
fibrosis
(Password required)